Comparative Pharmacology
Head-to-head clinical analysis: DYANAVEL XR versus LISDEXAMFETAMINE DIMESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYANAVEL XR versus LISDEXAMFETAMINE DIMESYLATE.
DYANAVEL XR vs LISDEXAMFETAMINE DIMESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dyanavel XR is a central nervous system stimulant that increases the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and increasing their release, thereby enhancing neurotransmission in the brain regions involved in attention and impulse control.
Lisdexamfetamine is a prodrug of dextroamphetamine, which blocks the reuptake of norepinephrine and dopamine from the synaptic cleft and increases their release into the extraneuronal space.
Initial dose: 5 mg orally once daily in the morning. Maximum dose: 20 mg once daily. May increase by 5–10 mg weekly based on tolerability and response.
30–70 mg orally once daily in the morning.
None Documented
None Documented
Mean terminal elimination half-life is approximately 8-10 hours for d-amphetamine and 12-14 hours for l-amphetamine; the extended-release formulation maintains therapeutic concentrations for 12-14 hours.
Terminal elimination half-life of lisdexamfetamine is approximately 1 hour (prodrug conversion), while dextroamphetamine (active moiety) has a half-life of 10-12 hours in adults. In children, half-life is slightly shorter (9-11 hours). Clinically, once-daily dosing provides symptom control for ADHD.
Approximately 30-50% of a dose is excreted unchanged in urine; remainder as metabolites (primarily hippuric acid) via renal elimination. Fecal excretion is minimal.
Primarily renal: approximately 95% of the dose is excreted in urine, with about 70% as intact lisdexamfetamine, 20% as dextroamphetamine and its metabolites (hippuric acid, benzoic acid), and minimal biliary/fecal elimination (<5%).
Category C
Category C
CNS Stimulant
CNS Stimulant